PH-HFpEF

Recent news mentioning PH-HFpEF

• 2026-08-10 — Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint
• 2026-08-10 — Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

Appears alongside

• Tenax Therapeutics Phase
• LEVEL

Browse the full archive →